Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-986393, GPRC5D CAR T cells, Arlo-cel
Arlocabtagene autoleucel · 3 trials · 2 indications
The number and percent of participants achieving BOR of partial response (PR) or better in quadruple class exposed participants received at least 4 prior lines of therapy (LOT)
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Arlocabtagene Autoleucel Cohort 1 | EXPERIMENTAL | - |
| Arlocabtagene Autoleucel Cohort 2 | EXPERIMENTAL | - |
| Arm A: BMS-986393 + Alnuctamab | EXPERIMENTAL | - |
| Arm B: BMS-986393 + Mezigdomide | EXPERIMENTAL | - |
| Arm C: BMS-986393 + Iberdomide | EXPERIMENTAL | - |
| Arm D: BMS-986393 + Elranatamab | EXPERIMENTAL | - |
| Arm E: BMS-986393 + Mezigdomide and Dexamethasone | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986393 | DRUG | Specified dose on specified days |
| Cyclophosphamide | DRUG | Specified dose on specified days |
| Fludarabine | DRUG | Specified dose on specified days |
| Daratumumab | DRUG | Specified dose on specified days |
| Pomalidomide | DRUG | Specified dose on specified days |
| Dexamethasone | DRUG | Specified dose on specified days |
| Carfilzomib | DRUG | Specified dose on specified days |
| Arlocabtagene Autoleucel | BIOLOGICAL | Specified dose on specified days |
| Alnuctamab | DRUG | Specified dose on specified days |
| Mezigdomide | DRUG | Specified dose on specified days |
| Iberdomide | DRUG | Specified dose on specified days |
| Elranatamab | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have relapsed or refractory multiple myeloma (RRMM). * Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monocl...
Top 20 of 25 competitors
Arlocabtagene autoleucel is an investigational CAR T cell therapy being developed by Bristol-Myers Squibb for multiple myeloma, including relapsed or refractory multiple myeloma. It is also known as BMS-986393. It is a GPRC5D-directed CAR T cell therapy and is currently in clinical development.
Arlocabtagene autoleucel is being studied for the treatment of multiple myeloma, including relapsed or refractory multiple myeloma (RRMM). It is an investigational therapy and has not been approved for any indication.
Arlocabtagene autoleucel targets GPRC5D. It is a GPRC5D-directed CAR T cell therapy, meaning the CAR T cells are engineered to recognize and attack cells expressing GPRC5D.
Arlocabtagene autoleucel is being developed by Bristol-Myers Squibb Company (ticker: BMY). The company is running clinical trials of the therapy in multiple myeloma.
Arlocabtagene autoleucel is in Phase 2 development. A Phase 3 trial is also recruiting, but the overall development stage is Phase 2. It is investigational and has not been approved by the FDA.
Arlocabtagene autoleucel is being studied in three recruiting trials: NCT06615479 (Phase 3, QUINTESSENTIAL-2), NCT06297226 (Phase 2), and NCT06121843 (Phase 1). All are in multiple myeloma or relapsed/refractory multiple myeloma.
Yes, Arlocabtagene autoleucel is also known as BMS-986393. Both names refer to the same GPRC5D-directed CAR T cell therapy being developed by Bristol-Myers Squibb.